A placebo controlled study to evaluate the safety and tolerability of repeat doses of SB-681323 in patients receiving methotrexate for rheumatoid arthritis.

Trial Profile

A placebo controlled study to evaluate the safety and tolerability of repeat doses of SB-681323 in patients receiving methotrexate for rheumatoid arthritis.

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Jun 2012

At a glance

  • Drugs Dilmapimod (Primary) ; Methotrexate
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 13 Jan 2012 Actual end date (Dec 2005) added as reported by ClinicalTrials.gov.
    • 13 Jan 2012 Actual patient number is 18 according to ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top